1. Search Result
Search Result
Results for "

prostate cancers

" in MedChemExpress (MCE) Product Catalog:

790

Inhibitors & Agonists

2

Screening Libraries

6

Biochemical Assay Reagents

60

Peptides

29

Inhibitory Antibodies

104

Natural
Products

24

Isotope-Labeled Compounds

7

Click Chemistry

6

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99188
    Carlumab
    2 Publications Verification

    CNTO 888

    CCR Cancer
    Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer .
    Carlumab
  • HY-P9992

    BAY-2315497; PSMA-TTC

    PSMA Inflammation/Immunology
    Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research .
    Pelgifatamab
  • HY-P99239

    HUJ-591

    PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
    Rosopatamab
  • HY-132896

    Histone Demethylase Cancer
    KDM4-IN-3 (Compound 15) is a KDM4 inhibitor (IC50 = 871 nM) that exhibits improved potency in biochemical assays. KDM4-IN-3 is cell-permeable and kills prostate cancer cells at low micro molar concentrations. KDM4-IN-3 inhibits growth of prostate cancer cell lines and increases the H3K9me3 abundance. KDM4-IN-3 can be studied in research for prostate cancer .
    KDM4-IN-3
  • HY-173476

    TcO-5

    PSMA Cancer
    TcO-ABX474 (TcO-5) is a potent prostate-specific membrane antigen (PSMA) inhibitor with a Kd value of 6.1 nM. TcO-ABX474 inhibits prostate cancer cell growth and metastasis. TcO-ABX474 is promising for research of prostate cancer .
    TcO-ABX474
  • HY-164395

    Phosphatase Inflammation/Immunology Cancer
    Sipuleucel-T is a cancer vaccine. Sipuleucel-T recognizes prostatic acid phosphatase (PAP), present PAP antigens, and stimulates the immune response against prostate cancer cells .
    Sipuleucel-T
  • HY-N10491

    P-glycoprotein Cancer
    Spongionellol A is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase‑dependent apoptosis. Spongionellol A can be used in the research of cancers, such as prostate cancer .
    Spongionellol A
  • HY-P991360

    MLN2704 antibody

    PSMA Cancer
    MLN 591 is a human monoclonal antibody (mAb) targeting PSMA. MLN 591 can be used in Prostate cancer research .
    MLN 591
  • HY-P10951

    (R)-PSMA I&T; (R)-PNT-2002

    PSMA Cancer
    Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .
    (R)-Zadavotide guraxetan
  • HY-N10492

    P-glycoprotein Cancer
    Spongionellol A analog 1, an analog of Spongionellol A (HY-10491), is a MDR1 (p-glycoprotein) inhibitor. Spongionellol A analog 1 has high cytotoxic activity and selectivity in prostate cancer cells by inducing caspase?dependent apoptosis. Spongionellol A analog 1 can be used in the research of cancers, such as prostate cancer .
    Spongionellol A analog 1
  • HY-110154

    Histone Demethylase Cancer
    NSC636819 is a competitive and selective inhibitor of KDM4A/KDM4B. KDM4A/KDM4B are potential progression factors for prostate cancer. NSC636819 has the potential for the research of cancer diseases, especially prostate cancer .
    NSC636819
  • HY-14249
    Bicalutamide
    15+ Cited Publications

    Androgen Receptor Autophagy Cancer
    Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .
    Bicalutamide
  • HY-106138

    Meterelin; MF 6001

    GnRH Receptor Cancer
    Avorelin (Meterelin) is a gonadotropin releasing hormone (GnRH) agonist. Avorelin can be used of the study of prostate cancer .
    Avorelin
  • HY-173597

    PARP Cancer
    ZINC43120769 is a PARP1 inhibitor. ZINC43120769 can be used in prostate cancer (PC) research .
    ZINC43120769
  • HY-P991503

    AZD0516 antibody

    ERK p38 MAPK Cancer
    Anti-STEAP2 Antibody (AZD0516 antibody) is a selective six-transmembrane epithelial antigen of prostate 2 (STEAP2) inhibitor. Anti-STEAP2 Antibody inhibits the proliferation, migration and invasion of prostate cancer cells by blocking the STEAP2-mediated ERK/MAPK signaling pathway. Anti-STEAP2 Antibody is promising for research of prostate cancer .
    Anti-STEAP2 Antibody
  • HY-136383
    AZA1
    1 Publications Verification

    Rac1/Cdc42-IN-1

    Ras Apoptosis Cancer
    AZA1 is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induces prostate cancer cells apoptosis and inhibits prostate cancer cells proliferation, migration and invasion .
    AZA1
  • HY-126412

    Apoptosis Cancer
    Neochamaejasmine A is a biflavonoid that can be isolated from the roots of Stellera chamaejasme L.. Neochamaejasmine A inhibits proliferation, induces cell cycle arrest and apoptosis in tumor cells. Neochamaejasmine A can be used in the research of cancers such as prostate cancer, hepatoma cancer .
    Neochamaejasmine A
  • HY-173626

    Androgen Receptor Cancer
    EN1441 is a covalent degrader targeting the androgen receptor (AR) with an EC50 value of 4.2 μM and its truncated variant AR-V7. EN1441 selectively and potently degrades both AR and AR-V7 in androgen-independent prostate cancer cells. EN1441 is promising for research of androgen-independent prostate cancers .
    EN1441
  • HY-118091A

    LY300502

    5 alpha Reductase Cancer
    Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer .
    Bexlosteride
  • HY-N7924

    Others Inflammation/Immunology Cancer
    Astragenol is an intermediate used for Astragenol derivative synthesis. Astragenol derivatives are promising anti-inflammatory agents for prostate cancer research .
    Astragenol
  • HY-201263

    Biochemical Assay Reagents Cancer
    p-SCN-Bn-TCMC is a bifunctional chelator. Its cyclen backbone binds Hg 2+, while its isothiocyanate group allows for conjugation to biomolecules. p-SCN-Bn-TCMC can be used in the research of prostate cancer .
    p-SCN-Bn-TCMC
  • HY-P6825

    LY4181530; PSMA-62

    PSMA Cancer
    PNT2001 (LY4181530) is a potent prostate specific membrane antigen (PSMA) ligand with an IC50 of 3.1 nM. PNT2001 can improve cellular internalization. 177Lu- and 225Ac-labeled PNT2001 can be used in prostate cancer research .
    PNT2001
  • HY-123560

    Bradykinin Receptor Cancer
    BKM-570 is a nonpeptide bradykinin antagonist with anticancer effects. BKM-570 can be used in the study of lung cancer, prostate cancer and ovarian cancer .
    BKM-570
  • HY-N15637

    Apoptosis Cancer
    Torularhodin is a carotenoid with anti-cancer activity. Torularhodin induces apopotsis of tumor cells and can be used for the study of prostate cancer .
    Torularhodin
  • HY-P10896

    Bombesin Receptor Cancer
    NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
    NOTA-P2-RM26
  • HY-129615

    PSMA Cancer
    MIP-1072 is a small molecule specific prostate-specific membrane antigen (PSMA) inhibitor. MIP-1072 inhibits the glutamate carboxypeptidase activity of PSMA with an Ki value of 4.6 nM. MIP-1072 is promising for research of prostate cancer .
    MIP-1072
  • HY-173639

    Antibody-Drug Conjugates (ADCs) Topoisomerase Cancer
    AZD0516 is a first-in-class antibody-drug conjugate (ADC) targeting six-transmembrane epithelial antigen of the prostate-2 (STEAP2). The anti-STEAP2 monoclonal antibody (mAb) is conjugated via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker (HY-173635) bearing the topoisomerase 1 inhibitor, Exatecan (HY-13631). AZD0516 can be used for the study of prostate cancer .
    AZD0516
  • HY-163610

    Ligands for Target Protein for PROTAC Aldose Reductase Cancer
    AKR1C3-IN-13 (Compound 4) is an AKR1C3 inhibitor. AKR1C3-IN-13 degrades AKR1C3 in prostate cancer cells .
    AKR1C3-IN-13
  • HY-156419

    PARP Cancer
    PARP7-IN-16 (compound 36) is a potent, selective and orally active inhibitor of PARP-1/2/7, with IC50s of 0.94, 0.87 and 0.21 nM, respectively. PARP7-IN-16 can be used for the research of breast cancer and prostate cancer .
    PARP7-IN-16
  • HY-153550

    Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging. PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    PSMA-1007
  • HY-148761
    Zadavotide guraxetan
    1 Publications Verification

    PSMA I&T; PNT-2002

    PSMA Cancer
    PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .
    Zadavotide guraxetan
  • HY-P5290

    Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research . HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-PSMA
  • HY-116904

    Apoptosis Akt Cancer
    Anticancer agent 253 (Compound 26) has anti-cancer activity against breast cancer cells, with IC50s of 6 μM (MCF-7), 10 μM (MDA-MB-231) and 6.4 μM (4T1 cells). Anticancer agent 253 arrests cell cycle and induces mitochondria-mediated apoptosis in cancer cells. Anticancer agent 253 inhibits Akt phosphorylation in human breast and prostate cancer .
    Anticancer agent 253
  • HY-P2450

    Antibiotic P168

    Fungal Antibiotic Infection Cancer
    Leucinostatin A (Antibiotic P168) is a nonapeptide exerting a remarkable activity especially against Candida albicans and Cryptococcus neoformans. Leucinostatin A is a hydrophobic nonapeptide antibiotic. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells. Antiprotozoal activies .
    Leucinostatin A
  • HY-14249S1

    Androgen Receptor Autophagy Isotope-Labeled Compounds Cancer
    Bicalutamide-d5 is deuterated labeled Bicalutamide (HY-14249). Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .
    Bicalutamide-d5
  • HY-14249R

    Reference Standards Androgen Receptor Autophagy Cancer
    Bicalutamide (Standard) is the analytical standard of Bicalutamide. This product is intended for research and analytical applications. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .
    Bicalutamide (Standard)
  • HY-162686

    c-Myc Cancer
    MYC-IN-3 (compound 37) is a potent MYC inhibitor. MYC-IN-3 shows antiproliferative activity. MYC-IN-3 shows anticancer activity. MYC-IN-3 has the potential for the research of prostate cancer .
    MYC-IN-3
  • HY-111061

    Estrogen Receptor/ERR Cancer
    GTX-758 is an orally active, nonsteroidal, selective agonist of ERα. GTX-758 plays an important role in castration resistant prostate cancer (CRPC) research .
    GTX-758
  • HY-P0013

    D-21074; ORF 23541

    GnRH Receptor Cancer
    Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer .
    Antide
  • HY-P0013A

    D-21074 acetate; ORF 23541 acetate

    GnRH Receptor Cancer
    Antide (D-21074) acetate is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer .
    Antide acetate
  • HY-124292
    Honokiol DCA
    1 Publications Verification

    Honokiol dichloroacetate

    Androgen Receptor Cancer
    Honokiol DCA (Honokiol dichloroacetate) is a dichloroacetate analog of Honokiol. Honokiol DCA can inhibit the growth of human prostate cancer cells in vitro and suppress the androgen receptor (AR) protein level .
    Honokiol DCA
  • HY-155502

    Aldose Reductase Cancer
    AKR1C3-IN-10 (compound 5r) is a selective AKR1C3 inhibitor (IC50=51 nM). AKR1C3-IN-10 shows good activity in a prostate cancer xenograft model .
    AKR1C3-IN-10
  • HY-W013272R

    HFT (Standard)

    Reference Standards Androgen Receptor Cancer
    Hydroxyflutamide (Standard) is the analytical standard of Hydroxyflutamide. This product is intended for research and analytical applications. Hydroxyflutamide (HF), an active metabolite of Flutamide, is a potent androgen receptor antagonist (IC50=700 nM). Hydroxyflutamide can be used for the research of prostate cancer .
    Hydroxyflutamide (Standard)
  • HY-P991414

    HIV Infection Cancer
    FGI-1011A6 is a human monoclonal antibody (mAb) targeting TSG101. FGI-1011A6 can be used in Prostate cancer and Viral infections research .
    FGI-1011A6
  • HY-P991410

    MEDI0641 antibody

    Wnt Cancer
    5T4_0108 (MEDI0641 antibody) is a human monoclonal antibody (mAb) targeting TPBG. 5T4_0108 can be used in breast and prostate cancer research .
    5T4_0108
  • HY-128808

    E3 ligase Ligand 12

    Ligands for E3 Ligase Cancer
    cIAP1 ligand 1 is the LCL161 derivative based IAP ligand. cIAP1 ligand 1 can be connected to the ABL ligand for protein by a linker to form SNIPER. cIAP1 ligand 1 can be used in prostate cancer research .
    cIAP1 ligand 1
  • HY-174808

    PSMA Radionuclide-Drug Conjugates (RDCs) Cancer
    SC691 is a PSMA inhibitor. SC691 can be labeled with 68Ga(III). SC691 can be used for imaging diagnosis of prostate cancer .
    SC691
  • HY-128172
    TRPM4-IN-2
    3 Publications Verification

    NBA

    TRP Channel Cancer
    TRPM4-IN-2 (NBA) is a potent transient receptor potential melastatin 4 (TRPM4) inhibitor with an IC50 value of 0.16 μM. TRPM4-IN-2 can be used for researching prostate cancer and colorectal cancer .
    TRPM4-IN-2
  • HY-16498

    PCK-3145

    Apoptosis Cancer
    Tigapotide (PCK-3145) is an anti-tumour peptide that reduces the development of skeletal metastases associated with prostate cancer. Tigapotide induces apoptosis and reduces tumour parathyroid hormone-related peptide (PTHrP) levels .
    Tigapotide
  • HY-120736

    Apoptosis Caspase Cancer
    MEB55 is an antitumor agent. MEB55 shows anti-proliferative activity. MEB55 has the potential for the research of prostate cancer .
    MEB55

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: